OncoC4 Welcomes Dr. Dan Janiak as Their New Chief Business Officer

OncoC4, Inc., a prominent player in the late clinical-stage biopharmaceutical arena, has made headlines with its recent appointment of Dr. Dan Janiak as Chief Business Officer. This strategic decision is seen as a pivotal moment in the company’s evolution as it continues to develop innovative therapies for cancer and immunological diseases.

A Leader with Extensive Experience

Dr. Janiak arrives at OncoC4 with over 15 years of experience in the biotechnology sector, specializing in the realms of oncology, neurology, and rare diseases. His impressive background encompasses corporate strategy, business development, venture investing, and new venture formation, making him a valuable asset to the company. Prior to joining OncoC4, he served as Executive Director of Business Development at AstraZeneca, where he spearheaded oncology platform transactions that leveraged cutting-edge technologies such as artificial intelligence and machine learning.

Yang Liu, Ph.D., the Co-founder, CEO, and Chief Scientific Officer at OncoC4, expressed enthusiasm about the new addition to the team. Liu noted, “We are delighted to welcome Dan to OncoC4 at such a crucial stage in our growth. His unique blend of scientific expertise, strategic acumen, and transaction experience will prove vital as we advance our pipeline.”

A Track Record of Success

Before his tenure at AstraZeneca, Dr. Janiak served as President and COO at Trotana Therapeutics. His career began at Taysha Gene Therapies, where he was instrumental in building the company from its inception to becoming a recognized entity in the gene therapy landscape, serving as Senior VP of Corporate Strategy and Business Development.

His previous roles also include strategy and corporate development positions at VelosBio and AveXis, further solidifying his well-rounded expertise. Early in his career, he worked in venture capital at Mercury Fund and In-Q-Tel, managing investments in therapeutics and medical technologies while advising nascent biopharmaceutical companies.

The Vision Ahead

Dr. Janiak emphasized the potential of OncoC4’s portfolio: “OncoC4 has built a compelling array of innovative oncology and immunology programs, and I am thrilled to join the company at this pivotal moment,” he stated. His focus will be on advancing business development and corporate strategy, establishing strategic partnerships, and creating opportunities that can expedite the delivery of new therapies to patients.

About OncoC4

Founded and headquartered in Rockville, Maryland, OncoC4 is dedicated to discovering and developing pioneering biologics for the treatment of various forms of cancer and immunological diseases, including neurodegenerative disorders. With a robust pipeline featuring first-in-class and best-in-class assets, OncoC4 is poised to make significant strides in the biopharmaceutical landscape.

One notable candidate in their pipeline is cesalatamig, a highly differentiated PD-1/VEGF bispecific antibody currently undergoing rapid clinical development across multiple oncology indications. Another promising therapy is Tasafustobart (ONC-841), a first-in-class anti-SIGLEC-10 antibody in Phase 2 trials for oncology and Phase 1 trials for neurodegenerative diseases. Additionally, the company has initiated a first-in-human trial for ONC-783, which is a T cell engager targeting a novel CD24 epitope expressed in numerous human cancers.

OncoC4 also collaborates with BioNTech to co-develop gotistobart (BNT316/ONC-392), aimed at targeting CTLA-4 in solid tumor indications, and is currently involved in a pivotal clinical trial in squamous non-small cell lung cancer.

As OncoC4 continues its commitment to cutting-edge research and development, the leadership of Dr. Janiak will undoubtedly play a critical role in furthering the company’s mission and enhancing the lives of patients battling challenging conditions.

For more information about OncoC4’s innovative therapies and ongoing research initiatives, please visit www.oncoc4.com.